Glycans are sugar-based molecules found on the surface of nearly every cell in your body. They are chains of simple sugars (monosaccharides) linked together, ranging from just a few sugar units to thousands. If DNA is your body’s blueprint and proteins are its machinery, glycans are the coating on that machinery, shaping how cells communicate, fight infections, and age over time.
Basic Structure of Glycans
A glycan’s identity depends on more than just which sugars it contains. The specific order of those sugars, the way they bond to each other, and any non-sugar molecules attached along the chain all contribute to its final shape and function. This structural flexibility is what makes glycans so diverse. They can be straight chains or branched like a tree, electrically neutral or carrying a charge, and built from identical sugar units or a mix of different ones.
That diversity is staggering. Some estimates place the number of distinct glycan structures in vertebrates at over one million. For comparison, the human genome contains roughly 25,000 protein-coding genes, and those genes account for less than 2% of total genomic DNA. The full catalog of glycans in a given organism, called the glycome, likely exceeds the complexity of both the proteome and transcriptome. Scientists still haven’t mapped the complete human glycome.
How Glycans Get Attached to Cells
Glycans rarely float around on their own in the body. They’re typically attached to proteins or fats on the cell surface, forming compounds called glycoproteins, glycolipids, and proteoglycans. The process of attaching glycans to proteins is called glycosylation, and it’s tightly controlled. Specialized enzymes called glycosyltransferases catalyze the formation of bonds between the glycan and its target protein, primarily inside two cellular compartments: the endoplasmic reticulum and the Golgi apparatus.
Glycosylation is sometimes confused with glycation, but the two are fundamentally different. Glycosylation is enzymatic, precise, and essential for normal cell function. Glycation is random and harmful. It happens when loose glucose molecules in the blood react with proteins without any enzyme guiding the process, ultimately producing compounds called advanced glycation end products (AGEs). AGEs accumulate with age and in conditions like diabetes, damaging tissues and promoting inflammation. Think of glycosylation as a carefully assembled sugar coating and glycation as rust.
What Glycans Do in the Body
Glycans serve a wide range of biological functions depending on where they sit and what they’re attached to.
On glycoproteins, they act as a physical shield. Mucins, the glycoproteins that line your respiratory and digestive tracts, use their dense glycan layers to protect tissue surfaces from microbial attachment. Viral glycoproteins use glycans to block antibodies from recognizing them. Glycans also help the cell’s quality control system: when a newly made protein folds incorrectly, glycan tags help route it to the cell’s recycling machinery for destruction.
Proteoglycans, which carry especially large glycan chains, are structural workhorses in the spaces between cells. They maintain tissue integrity, control how porous a tissue is, and provide the scaffolding that holds connective tissues together. Glycolipids, meanwhile, sit in the cell membrane and help organize it into functional zones. Certain glycolipids called gangliosides can modulate how growth signals from hormones like insulin and epidermal growth factor are received.
Cell Signaling and Immune Function
Because glycans sit on the outer surface of cells, they’re perfectly positioned to mediate communication between cells. Most cell surface receptors are themselves glycosylated, and many specifically recognize glycans on other cells or molecules. This makes glycans central players in signaling.
In embryonic development, the Notch receptor, which controls cell fate decisions, requires a specific type of glycan modification to function. In the adult nervous system, a glycan-binding protein on myelin sheaths binds to glycans on nerve fibers to regulate whether axons can grow. In the immune system, specific glycan patterns on B cells and T cells are essential for activating or shutting down immune responses. Enzymes on the cell surface can also rapidly remodel glycans, acting like a switch that turns signaling pathways on or off in real time. One enzyme, for instance, strips sulfate groups from glycans to release signaling molecules that then activate growth pathways. Another removes a sugar called sialic acid from cell surface glycans, which can either trigger tissue-building processes or amplify growth signals depending on context.
How Pathogens Exploit Glycans
Viruses, bacteria, and other pathogens have evolved to hijack the glycan language on cell surfaces. Many viruses bind to specific host glycans as the first step of infection, using them as attachment points or direct entry receptors.
- Influenza viruses use a surface protein to latch onto sialic acid-containing glycans. Avian flu strains prefer one type of sialic acid linkage, while human flu strains prefer another. This difference is a major factor in determining which species a flu virus can infect.
- Noroviruses recognize blood group-related glycans on gut cells as attachment factors, with different norovirus strains binding to different sugar components of these glycans.
- Human papillomavirus (HPV) binds to heparan sulfate glycans on cell surfaces to initiate entry.
Understanding these glycan-pathogen interactions has become a key area for developing antiviral therapies and vaccines.
Glycans as Disease Biomarkers
Because glycan patterns change in disease states, they’re increasingly useful as diagnostic markers, particularly in cancer. Tumor cells often display abnormal glycan profiles on their surfaces, and some of these glycan-bearing proteins have become standard clinical biomarkers. CA 125 is a glycoprotein marker used in ovarian cancer screening. CA 19-9 is used as a pancreatic cancer biomarker and can help distinguish pancreatic cancer from other causes of jaundice. CA 15-3 is used to monitor breast cancer recurrence. Carcinoembryonic antigen (CEA), a heavily glycosylated protein, shows changes in colorectal, bladder, breast, pancreatic, and lung cancers.
Alterations in glycosylation are not limited to cancer. Abnormal glycan patterns have been associated with infections and autoimmune disorders as well, making glycan analysis a broadly useful diagnostic tool.
Glycans and Biological Aging
One of the more striking recent findings involves glycans on immunoglobulin G (IgG), the most abundant antibody in the blood. The sugar structures on IgG act as a switch between pro-inflammatory and anti-inflammatory activity. As people age, specific glycan changes on IgG shift it toward a more inflammatory state.
A study of over 5,100 individuals across four European populations found that a combination of three IgG glycans could explain up to 58% of the variance in chronological age, significantly more than telomere length, which has long been the go-to marker for biological aging. After accounting for chronological age, the remaining variation in these glycans correlated strongly with physiological measures of biological age. In other words, glycan patterns don’t just track how old you are; they reflect how old your body acts. This led to the development of a GlycanAge index, which predicts chronological age within about 9.7 years and captures meaningful differences in biological aging between individuals. The declining addition of galactose sugars to IgG with age appears to actively promote the chronic, low-grade inflammation sometimes called “inflammaging.”
Glycans in Drug Development
Glycans play a critical role in how well biologic drugs work, particularly monoclonal antibodies. These therapeutic antibodies rely on glycan patterns in their crystallizable region (Fc region) to interact with immune cells. The specific sugars attached to an antibody affect how strongly it triggers immune responses like complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, both important mechanisms for destroying cancer cells or infected cells.
Removing glycans from antibodies doesn’t just reduce their effectiveness. It also makes them physically less stable: they become more sensitive to heat, more vulnerable to being broken down by enzymes, and more prone to clumping together, which directly affects shelf life. For these reasons, pharmaceutical companies use glycoengineering to produce antibodies with precisely tailored sugar profiles, ensuring the final product has both the right biological activity and the physical stability needed for storage and transport.
How Scientists Study Glycans
Mapping glycan structures is technically challenging because of their branching complexity and the many structural variations that share identical masses. Mass spectrometry is the primary tool, used to analyze glycans released from glycoproteins, proteoglycans, and glycolipids. The mass of a glycan, when measured with sufficient accuracy, directly reveals its composition in terms of sugar types like hexoses, deoxyhexoses, and N-acetylhexosamines.
Because mass alone can’t always distinguish between structural look-alikes, researchers often pair mass spectrometry with separation techniques. Porous graphitized carbon chromatography is particularly powerful at separating glycan isomers that would otherwise be indistinguishable. Other common approaches include a type of chromatography that sorts molecules by how they interact with water (HILIC) and capillary electrophoresis. For pinpointing exactly where glycans sit on a protein, specialized fragmentation methods can break apart glycan-protein complexes in ways that preserve either the sugar portion or the protein backbone, giving researchers complementary pieces of the puzzle.